| Vilaprisan, a new, promising, selective progesterone receptor modulator, exhibits an attractive pharmacokinetic profile with good absolute oral bioavailability, suitable for low-dose once-daily administration. |
| Vilaprisan is predominantly eliminated via hepatic biotransformation. |
| The pivotal role of cytochrome P450 3A4 in the elimination of vilaprisan was confirmed in a drug–drug interaction study with the strong cytochrome P450 3A4 inhibitor itraconazole. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.